Genomic impact of transient low-dose decitabine treatment on primary AML cells

Acute myeloid leukemia (AML) is characterized by dysregulated gene expression and abnormal patterns of DNA methylation; the relationship between these events is unclear. Many AML patients are now being treated with hypomethylating agents, such as decitabine (DAC), although the mechanisms by which it...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Klco, Jeffery M., Spencer, David H., Lamprecht, Tamara L., Sarkaria, Shawn M., Wylie, Todd, Magrini, Vincent, Hundal, Jasreet, Walker, Jason, Varghese, Nobish, Erdmann-Gilmore, Petra, Lichti, Cheryl F., Meyer, Matthew R., Townsend, R. Reid, Wilson, Richard K., Mardis, Elaine R., Ley, Timothy J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587326/
https://ncbi.nlm.nih.gov/pubmed/23297133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-09-459313
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados